Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes.

Ulf Hannelius Craig A Beam Johnny Ludvigsson

Published in: Diabetologia (2020)

GAD65-specific immunotherapy has a significant effect on C-peptide retention in individuals with recent-onset type 1 diabetes who have the DR3-DQ2 haplotype. Graphical abstract.

Keyphrases

type diabetes
glycemic control
editorial comment
celiac disease
cardiovascular disease
insulin resistance